Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

These high-quality businesses have suffered recent share price setbacks. This writer thinks they're now worth considering for a Stocks and Shares ISA. The post 2 beaten-down shares to consider for a ...

It's not just celebrities and TikTok creators jumping on the weight loss drug hype - more than 500,000 people in the UK are ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.